CERo raises up to $8M in Series D convertible; believes meets Nasdaq equity requirement

CERO THERAPEUTICS HOLDINGS, INC.

Closed initial $5M of up to $8M Series D convertible preferred; conversion price $0.78, floor $0.156.
Believes meets $2.5M stockholders' equity after placement, prior $2.3M equity line & $4.1M Feb offering; delisting risk remains.
Series D ranks senior to Series A & B, pari passu with Series C; 25% redemption premium on bankruptcy or company optional redemption.
Proceeds to fund IND allowances, MDACC site activation, and extend cash runway, per press release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.